“a favorable trend”

For Stage IC patients, those receiving chemotherapy ( n = 744) had a favorable trend in OS compared to those not receiving chemotherapy ( n = 145), with 5-year OS rates of 85.1% and 77.5%, although the difference was not statistically significant ( p =0.116).

This trial also included a subgroup analysis focused specifically on pNET patients, which demonstrated a favorable trend for disease control in those receiving lanreotide (HR = 0.58; 95% CI, 0.32–1.04) 43 .

Additionally, results indicate a favorable trend in reducing VAS-B scores.

The skewness and entropy AUCs exhibited a favorable trend in the intermediate energy range.

A favorable trend was also observed for Erythrocyte sedimentation rate, PSA and Total Cholesterol.

20 According to the hierarchical testing, OS was significantly improved with tislelizumab over chemotherapy in patients with PD-L1 TAP ≥ 10% (HR, 0.54), and in the prespecified exploratory analysis, tislelizumab also showed a favorable trend of improvement in OS versus chemotherapy in patients with PD-L1 TAP < 10% (HR, 0.82).

Three‐year RFS in the patients with severe obesity was not significantly different from that in those with mild obesity, although a favorable trend was shown.

A recent study showed a favorable trend in reducing the availability of processed food depicting warning seals [ 9 ].

Conclusions Despite a favorable trend over the past decade, Asian participants and authors from APAC remain significantly underrepresented in seminal cardiometabolic trials; barriers to trial conduct and leadership in this region must be addressed.

Individual studies comparing CC-Only CPR versus conventional CPR instructions with rescue ventilation show a favorable trend towards CC-Only CPR instructions [ 26 - 28 ].

Thus, a single-center study with a prospective cohort of 44 adult glioblastoma patients combined volumetric MRI-based extent-of-resection analysis with rapid PCR-based detection of TERT promoter mutation at the surgical margin and found that achieving an undetectable molecular margin was associated with significantly prolonged PFS and a favorable trend for OS [ 102 ].

Both when VR training was analyzed and reviewed separately, and when compared to traditional training, the findings exhibited predominantly promising outcomes, reflecting a favorable trend in the study.

Overall survival showed a favorable trend.

Moreover, pembrolizumab showed a favorable trend in overall survival (OS) (HR: 0.72, 95%CI: 0.51-1.02).

In another study on hospitalized COVID-19 patients, the percentage of hypertensive patients taking ACE-I/ARB did not differ between those with severe and non-severe infection or between non-survivors and survivors, with a favorable trend for ACE-I/ARB, although adjusted analysis was not performed [ 7 ].

In a recent, but smaller trial, involving 26 patients with acute ischemic stroke, ReIP showed a favorable trend toward improving clinical outcomes at 3 months as well as an increase in the circulating levels of a putative biomarker, heat shock protein-27 ( 14 ).

Near negative fusional vergence showed a favorable trend in the DG, with higher mean values in both break and recovery points; however, the differences did not reach statistical significance ( p = 0.110 for break and p = 0.060 for recovery).

Multivariate analysis adjusting for age, gender, race, treatment, and biomarkers suggested a favorable trend for fusion-positive status ( Figure 4B ).

Moreover, our dynamic analysis of the network revealed increasingly dense and more transfers into the hubs, suggesting a favorable trend of regionalized care.

Although the OS benefit from PARP inhibitors was limited, the results should be interpreted with caution, considering that they had a favorable trend and were only marginally insignificant at a 95% CI level.

In fact, the dark current showed a favorable trend, decreasing from an initial value of 1.29 × 10 −6 mA/cm 2 to approximately 2.5 × 10 −7 mA/cm 2 over the 240-day period.

As can be seen from Table 1 , the mean value of urban green transformation reached 1.046 over the 12-year period, which is greater than unity and represents a favorable trend of green transformation with an average annual growth rate of 4.6 %.

In the CT cohort, subgroup analysis indicated a favorable trend of DFS for patients with KRAS / NRAS / BRAF mutations and receiving up to four cycles of conversion therapy ( P _interaction, 0.005 and 0.013, respectively).

Although not reaching statistical significance, there was a favorable trend toward slowed global VF MD progression after supplementation began, suggesting a possible neuroprotective effect.

On the other hand, nal-IRI + 5-FU/LV showed a favorable trend in HR for OS compared with S-1 in the complete-case analysis dataset, but a statistical significance showed marginal in contrast to multiple imputed dataset.